# South Korea Keytruda Market > South Korea Keytruda Market Research Report By Cancer Type (Melanoma, Lung cancer, Hodgkin lymphoma, Stomach cancer, Urothelial carcinoma) and By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.2% - **2024:** $ 677.17 Million - **2025:** $ 739.48 Million - **2035:** $ 1,783.33 Million - **Key Players:** Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US) **Report ID:** MRFR/HC/43640-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-keytruda-market-45320 --- ## Market Summary ## **South Korea Keytruda Market Overview** As per MRFR analysis, the South Korea Keytruda Market Size was estimated at 620.19 (USD Million) in 2024The South Korea Keytruda Market Industry is expected to grow from 677.25(USD Million) in 2025 to 1,167.95 (USD Million) by 2035. The South Korea Keytruda Market CAGR (growth rate) is expected to be around 5.079% during the forecast period (2025 - 2035). **Key South Korea Keytruda Market Trends Highlighted** In South Korea, the Keytruda market has been experiencing significant growth driven by a rising prevalence of cancer cases and a strong focus on innovative immunotherapies. The increasing awareness of cancer treatment options, along with government initiatives to improve healthcare access, has contributed to the advancements in oncology treatments, including Keytruda. The South Korean healthcare system has been emphasizing personalized medicine, positioning Keytruda favorably as it is often used for various types of cancers, including melanoma and lung cancer.  Opportunities in the South Korean market revolve around expanding access to Keytruda in underserved regions and enhancing patient education regarding treatment options.The government supports research and development in biotechnology, opening avenues for collaboration between pharmaceutical companies and local research institutions. Additionally, as South Korean demographics shift and the aging population increases, there will be greater demand for effective cancer therapies, presenting potential for market expansion. Recent trends in the South Korean Keytruda market indicate an uptick in combination therapies, where Keytruda is being used alongside other anti-cancer drugs to enhance therapeutic efficacy.  Patients are increasingly favoring treatment plans that leverage the strengths of multiple medications, and clinicians are adopting these approaches based on their clinical experiences and outcomes.Furthermore, regulatory approvals for expanded indications of Keytruda create new pathways for treatment, showcasing the dynamic nature of the South Korean healthcare sector. The commitment to cutting-edge research and patient-centered care solidifies South Korea’s position as a key player in the evolving landscape of cancer therapies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Keytruda Market Drivers** Increasing Incidence of Cancer The South Korea Keytruda Market Industry is significantly driven by the increasing incidence of cancer cases within the region. Recent statistics indicate that the number of cancer patients in South Korea is expected to rise, with the Korean Cancer Association reporting over 240,000 new cases in 2020 alone, which is an increase from about 230,000 cases in 2019. This uptick demonstrates a growing patient population requiring effective treatment options like Keytruda.Additionally, with South Korea's elderly population increasing due to higher life expectancy, the prevalence of age-related cancers is also on the rise. Research by the National Statistical Office of South Korea suggests a projected 24% increase in the population aged 65 and older by 2030, contributing to a higher demand for innovative cancer therapies such as Keytruda. The need for effective immunotherapy options will continue to fuel the growth of the South Korea Keytruda Market Industry as healthcare providers look for advanced treatments that improve patient outcomes. Government Support and Policy Initiatives Government initiatives play a crucial role in supporting the South Korea Keytruda Market Industry. The South Korean government has actively pursued policies to enhance cancer care and promote innovative treatment options. Initiatives, such as the 'Korean National Cancer Control Plan,' aim to improve cancer prevention, diagnosis, and treatment, facilitating quick access to breakthrough therapies like Keytruda. The government has allocated funds and resources to enhance cancer research and expedite the approval process for new cancer drugs, demonstrating a commitment to improving healthcare.For instance, the Ministry of Health and Welfare's recent initiatives to subsidize cancer drug treatments indicate an effort to improve affordability and accessibility for patients. This regulatory backing not only fosters a favorable environment for Keytruda uptake but also propels growth within the South Korea Keytruda Market Industry by creating awareness and facilitating broader access to cutting-edge treatment options. Growth in Healthcare Infrastructure The advancement of healthcare infrastructure within South Korea is another significant driver of the South Korea Keytruda Market Industry. The country boasts a highly developed healthcare system characterized by state-of-the-art medical facilities and innovative health technologies. According to the Korean Hospital Association, South Korea's healthcare sector has seen a 9% yearly increase in expenditures over the last five years, enabling institutions to invest in advanced treatment modalities.The growing number of specialty cancer treatment centers and the widespread availability of immunotherapy are critical in the adoption of Keytruda, enhancing patient access to this essential medication.  Moreover, collaborations with leading biopharmaceutical companies and research institutions are propelling advancements in treatment protocols, making Keytruda an integral part of cancer treatment regimens in the country. As healthcare infrastructure continues to improve, the uptake of advanced therapies like Keytruda is expected to strengthen significantly, contributing to the overall growth of the South Korea Keytruda Market Industry. Rising Awareness and Education on Immunotherapy There is a growing awareness and understanding of immunotherapy among healthcare providers and patients in South Korea, which is positively influencing the South Korea Keytruda Market Industry. Educational initiatives led by organizations such as the Korean Society of Clinical Oncology emphasize the benefits and advancements of immunotherapy in cancer treatment. Increased participation in workshops, conferences, and community outreach programs has enhanced both physician and patient knowledge regarding immunotherapeutic options like Keytruda.An indication of this growing awareness is reflected in surveys where over 70% of oncologists expressed a strong understanding of immunotherapy's role in modern cancer care.  As patients become more informed and increasingly advocate for advanced treatments, their willingness to pursue therapies like Keytruda further drives market demand. Ultimately, this rising awareness ensures that immunotherapy, particularly options like Keytruda, occupies a critical niche in the evolving landscape of oncological treatments within the South Korea Keytruda Market Industry. **South Korea Keytruda Market Segment Insights** **Keytruda Market Cancer Type Insights** The South Korea Keytruda Market demonstrates substantial activity within the Cancer Type segment, reflecting a growing focus on innovative immunotherapeutic solutions for various malignancies. The segment comprises distinct types of cancers, each contributing uniquely to the overall landscape. Melanoma has been noteworthy due to its increasing incidence in South Korea, paralleling global trends that underscore the need for enhanced treatment modalities. Lung cancer, being one of the most prevalent forms of cancer in the region, indicates a high demand for effective therapies like Keytruda, which has shown promising outcomes in clinical trials and offers hope for improved patient survival rates. Hodgkin lymphoma, though less common, requires effective therapeutic strategies, making the availability of immunotherapy crucial in guiding treatment decisions for affected patients. Stomach cancer, unfortunately, remains a leading cause of cancer-related mortality in South Korea, further emphasizing the necessity for advanced treatment options. As identified by the South Korean government, Urothelial carcinoma poses a rising healthcare challenge within the oncology sector, highlighting the importance of innovative therapies like Keytruda in addressing this cancer type. The growing prevalence of these cancers in South Korea is influenced by factors such as lifestyle changes, environmental factors, and genetic predispositions. Together, these elements have made the Cancer Type segment an area of significant focus within the South Korea Keytruda Market revenue. By addressing these cancers specifically, medical professionals aim to provide tailored therapies to enhance the quality of care and improve clinical outcomes. The increasing adoption of Keytruda in these areas not only reflects advancements in cancer treatment but also underscores the evolving landscape of oncology in South Korea, steering towards a more personalized approach to patient care and disease management. Overall, the Cancer Type insights reveal that addressing these cancer types is vital to enhance the South Korea Keytruda Market segmentation, given their implications for public health and clinical practice. As the landscape of cancer management continues to evolve, opportunities exist for further research and development aimed at improving therapeutic efficacy and expanding treatment options for diverse cancer types prevalent in South Korea. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Keytruda Market Distribution Channel Insights** The distribution channel segment of the South Korea Keytruda Market plays a vital role in ensuring effective access to this important medication. In South Korea, Hospital Pharmacies significantly contribute to the availability of Keytruda by facilitating patient access through health institutions that provide specialized care. These pharmacies are known for their capability to handle complex oncology medications and are often the first point of contact for patients receiving treatment. Specialty Pharmacies also hold a crucial position in the market, focusing on the tailored distribution of Keytruda, which requires specific handling, storage, and patient support due to its unique characteristics.The combination of these channels ensures a structured approach to medication distribution, addressing patient needs and aligning with the growing demand for cancer treatments.  The South Korean government has been actively promoting initiatives to enhance cancer care, thereby supporting the expansion of pharmacy services in hospitals and specialty settings. This focus on patient-centric care enhances market dynamics and reflects positively on the South Korea Keytruda Market revenue, highlighting critical growth drivers and opportunities within the evolving therapeutic landscape. **South Korea Keytruda Market Key Players and Competitive Insights** The South Korea Keytruda market is marked by an intense competitive landscape driven by the increasing demand for innovative cancer therapies. Keytruda, an immune checkpoint inhibitor known for its efficacy in treating various cancers, creates a dynamic environment where pharmaceutical companies vie for market share amidst emerging biosimilars and generic options. As the regulatory framework evolves and healthcare expenditure rises, the competition intensifies among local and international players. The market is characterized by a blend of well-established pharmaceutical firms and rapidly growing biotechnology enterprises, each leveraging cutting-edge research capabilities and strategic partnerships to enhance their product offerings and market presence.  The interplay of pricing strategies, distribution networks, and marketing efforts also contributes to the competitive dynamics that define this market.Ildong Pharmaceutical has carved out a notable position in the South Korea Keytruda market, showcasing strengths that allow it to stand out amidst competition. With a strong focus on research and development, Ildong Pharmaceutical has invested significantly in oncology, positioning itself as a proactive player in addressing the need for effective cancer treatments. The company's strategic alliances with global research institutions enhance its capabilities in developing innovative therapies to combat various types of cancer. This collaboration not only bolsters Ildong Pharmaceutical’s portfolio but also enables it to meet stringent regulatory standards.  Furthermore, Ildong Pharmaceutical’s robust sales and distribution networks within South Korea ensure its products reach clinicians and hospitals effectively, solidifying its presence and reputation within the highly competitive oncology landscape.LG Chem operates with a strategic focus on research and innovation within the South Korea Keytruda market, where it emphasizes the importance of biopharmaceuticals in its overall business strategy. With a diverse range of key products and services in oncology, LG Chem has positioned itself as a significant contender in the development and distribution of cancer therapies, including those related to immune checkpoint inhibitors. Its strengths lie in advanced research facilities and a dedicated workforce committed to developing innovative solutions for patients.  LG Chem has engaged in various mergers and acquisitions to amplify its capabilities and broaden its therapeutic portfolio, ensuring a competitive edge in the market. The company’s strong relationships with healthcare providers and its commitment to quality and accessibility further enhance its presence in the South Korean market, allowing it to meet the evolving needs of medical professionals and patients alike. **Key Companies in the South Korea Keytruda Market Include** **South Korea Keytruda Market Industry Developments** The South Korea Keytruda market has witnessed significant movements recently, particularly concerning collaborations and advancements among key players. In late 2022, Merck & Co. announced the expansion of its partnership with Hanmi Pharmaceutical to enhance oncology offerings, facilitating the development of innovative treatments alongside Keytruda. Furthermore, Ildong Pharmaceutical and LG Chem have embarked on joint research projects to explore new immunotherapies, signaling a focus on enhancing pharmaceutical capabilities in the sector.In terms of market growth, Celltrion reported a boost in its stock market valuation following positive clinical trial results linked to immunotherapy lines related to Keytruda.  Samsung Biologics and SK Pharmteco are also solidifying their positions by upgrading their manufacturing capabilities ensuring efficient production of biologics, which is pivotal for the growing demand Keytruda in South Korea. Additionally, the South Korean government has been actively promoting research and development in the biopharmaceutical sector, contributing to an impressive increase in market valuations among companies engaged in Keytruda research and development, particularly over the last two years. **South Korea Keytruda Market Segmentation Insights** **Keytruda Market****Cancer Type****Outlook** **Keytruda Market****Distribution Channel****Outlook** ## Market Drivers ### Emerging Patient Demographics The emergence of new patient demographics is reshaping the keytruda market in South Korea. An aging population, coupled with lifestyle changes, has led to an increase in cancer diagnoses among younger individuals. This demographic shift is prompting healthcare providers to consider keytruda as a first-line treatment option for a broader range of patients. In 2025, it is estimated that the incidence of cancer among individuals aged 30-50 will rise by 15%, creating a larger patient base for keytruda. As healthcare systems adapt to these changing demographics, the keytruda market is likely to experience significant growth. ### Rising Healthcare Expenditure The increase in healthcare expenditure in South Korea is a significant driver for the keytruda market. As the government and private sectors invest more in healthcare, there is a corresponding rise in the availability of advanced cancer treatments. In 2025, healthcare spending is projected to reach approximately 9% of the GDP, reflecting a commitment to improving patient outcomes. This financial commitment is likely to facilitate greater access to keytruda, as hospitals and clinics expand their treatment offerings. Consequently, the keytruda market may see a substantial uptick in demand as more patients are able to afford cutting-edge therapies. ### Advancements in Clinical Research Ongoing advancements in clinical research are playing a crucial role in the expansion of the keytruda market. South Korean research institutions are increasingly involved in clinical trials that explore the efficacy of keytruda in various cancer types. Recent studies indicate that keytruda has shown promising results in treating melanoma and lung cancer, leading to a potential increase in its adoption. The South Korean government has allocated substantial funding for cancer research, which may further enhance the development of new treatment protocols involving keytruda. This focus on research is likely to bolster the keytruda market as new data emerges. ### Increasing Awareness of Immunotherapy The growing awareness of immunotherapy as a viable treatment option for various cancers is driving the keytruda market in South Korea. Educational campaigns by healthcare providers and patient advocacy groups have contributed to a better understanding of the benefits of immunotherapy. As patients become more informed about their treatment options, the demand for keytruda is likely to rise. In 2025, it is estimated that approximately 30% of cancer patients in South Korea are considering immunotherapy as part of their treatment plan. This shift in patient preference is expected to significantly impact the keytruda market, as more individuals seek out this innovative therapy. ### Government Initiatives for Cancer Treatment Government initiatives aimed at improving cancer treatment accessibility are influencing the keytruda market in South Korea. The Ministry of Health and Welfare has implemented policies to subsidize cancer treatments, including immunotherapy options like keytruda. These initiatives are designed to reduce the financial burden on patients, making keytruda more accessible to a broader population. As a result, the market is expected to experience growth, with projections indicating a potential increase in keytruda prescriptions by 20% over the next few years. This supportive regulatory environment is likely to enhance the overall landscape of the keytruda market. ## Future Outlook The [Keytruda Market](https://www.marketresearchfuture.com/reports/keytruda-market-19207) in South Korea is projected to grow at a 9.2% CAGR from 2025 to 2035, driven by increasing cancer prevalence and advancements in immunotherapy. **New opportunities:** - Expansion of telehealth services for remote patient monitoring - Development of combination therapies with emerging oncology drugs - Investment in personalized medicine approaches for tailored treatments By 2035, the keytruda market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Cancer Type: Melanoma (Largest) vs. Lung Cancer (Fastest-Growing) In the South Korea keytruda market, melanoma accounts for the largest share, driven by increased awareness and early detection methods among patients. Lung cancer follows closely, benefiting from advancements in diagnostic techniques and the growing prevalence of smoking-related cases. Other cancers like Hodgkin lymphoma, stomach cancer, and urothelial carcinoma hold smaller market shares, yet they contribute to the overall landscape by addressing specific patient needs and treatment options. The growth trends within this segment indicate a robust expansion, particularly in lung cancer, which has emerged as the fastest-growing category. Factors such as innovative therapies, enhanced clinical outcomes, and supportive government policies to improve lung cancer screening are fueling this growth. Additionally, melanoma continues to thrive as a priority area due to ongoing research and development dedicated to immuno-oncology treatments, positioning it as a key player in the treatment landscape. Melanoma: Dominant vs. Lung Cancer: Emerging Melanoma stands as the dominant force within the South Korea keytruda market, characterized by high incidences and significant investment in research and development. This cancer type benefits from established treatment protocols and is often prioritized due to its visibility in the dermatological landscape. It possesses a well-structured support system, enabling better patient access to therapies. Conversely, lung cancer is emerging rapidly, driven by increasing diagnostic capabilities and a growing focus on targeted therapies. This segment is gaining momentum owing to heightened awareness about lung health and the effectiveness of new treatment modalities. Both segments are critical, yet their market dynamics offer unique challenges and opportunities that shape their respective trajectories. ### By Distribution Channel: Hospital Pharmacies (Largest) vs. Specialty Pharmacies (Fastest-Growing) In the South Korea keytruda market, Hospital Pharmacies hold the largest market share, benefiting from established relationships with healthcare providers and patients relying on hospital settings for treatments. Specialty Pharmacies, although smaller in share, are rapidly gaining traction as they cater to specific patient needs and provide specialized care for keytruda therapies. The growth of Specialty Pharmacies is driven by the increasing demand for personalized medicine and the rise of chronic diseases requiring long-term management. Innovations in pharmaceutical services, along with the growing preference for targeted therapies, have contributed to this segment's expansion. As healthcare continues to evolve, both Hospital and Specialty Pharmacies are poised to play crucial roles in the distribution of keytruda in the market. Hospital Pharmacies: Dominant vs. Specialty Pharmacies: Emerging Hospital Pharmacies dominate the South Korea keytruda market due to their extensive reach and critical role in patient care. They typically have robust infrastructures and established relationships with medical professionals, facilitating efficient patient access to treatments. Meanwhile, Specialty Pharmacies are emerging as vital players, driven by the increasing complexity of patient therapies. They focus on providing tailored services and education to patients, which enhances adherence to treatment regimens. The combination of specialized knowledge, inventory of high-cost drugs, and supportive patient services positions Specialty Pharmacies as significant contributors to the future growth of the market. ## Competitive Benchmarking The competitive dynamics within the keytruda market exhibit a landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Merck & Co (US), Bristol-Myers Squibb (US), and Roche Holding AG (CH) are at the forefront, each leveraging distinct strategies to enhance their market presence. Merck & Co (US) continues to focus on expanding its clinical trial portfolio, particularly in combination therapies, which appears to be a pivotal strategy for maintaining its leadership position. Meanwhile, Bristol-Myers Squibb (US) emphasizes strategic partnerships to bolster its research capabilities, particularly in immuno-oncology, thereby enhancing its competitive edge. Roche Holding AG (CH) is investing heavily in digital transformation initiatives, aiming to streamline operations and improve patient outcomes through data analytics and personalized medicine.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure is moderately fragmented, with a few dominant players exerting considerable influence over pricing and innovation. This fragmentation allows for niche players to emerge, yet the collective strength of the major companies shapes the competitive environment significantly, often dictating market trends and consumer preferences. In October Merck & Co (US) announced a strategic collaboration with a leading South Korean biotech firm to enhance its research capabilities in the region. This partnership is likely to facilitate localized clinical trials, thereby accelerating the development of new therapies tailored to the South Korean population. Such collaborations not only enhance Merck's operational efficiency but also position it favorably within the local market, potentially increasing its market share. In September Bristol-Myers Squibb (US) launched a new initiative aimed at expanding access to its immunotherapy treatments in South Korea. This initiative includes partnerships with local healthcare providers to ensure that patients have better access to cutting-edge therapies. The strategic importance of this move lies in its potential to enhance patient outcomes while simultaneously strengthening the company's brand loyalty in a competitive market. In August Roche Holding AG (CH) unveiled a new digital platform designed to integrate patient data with treatment protocols, enhancing the precision of its therapeutic offerings. This initiative underscores Roche's commitment to digitalization and personalized medicine, which are increasingly becoming critical differentiators in the keytruda market. By leveraging technology, Roche aims to improve treatment efficacy and patient engagement, thereby solidifying its competitive position. As of November the keytruda market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) into therapeutic development. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. The evolution of competitive differentiation appears to be shifting from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition suggests that companies that prioritize these areas may be better positioned to thrive in the evolving market. ## Recent News & Developments The South Korea Keytruda Market has witnessed significant movements recently, particularly concerning collaborations and advancements among key players. In late 2022, Merck & Co. announced the expansion of its partnership with Hanmi Pharmaceutical to enhance oncology offerings, facilitating the development of innovative treatments alongside Keytruda. Furthermore, Ildong Pharmaceutical and LG Chem have embarked on joint research projects to explore new immunotherapies, signaling a focus on enhancing pharmaceutical capabilities in the sector.In terms of market growth, Celltrion reported a boost in its stock market valuation following positive clinical trial results linked to immunotherapy lines related to Keytruda.  Samsung Biologics and SK Pharmteco are also solidifying their positions by upgrading their manufacturing capabilities ensuring efficient production of biologics, which is pivotal for the growing demand Keytruda in South Korea. Additionally, the South Korean government has been actively promoting research and development in the biopharmaceutical sector, contributing to an impressive increase in market valuations among companies engaged in Keytruda research and development, particularly over the last two years. ## Report Scope | MARKET SIZE 2024 | 677.17(USD Million) | | --- | --- | | MARKET SIZE 2025 | 739.48(USD Million) | | MARKET SIZE 2035 | 1783.33(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US) | | Segments Covered | Cancer Type, Distribution Channel | | Key Market Opportunities | Emerging immunotherapy advancements and regulatory support enhance growth potential in the keytruda market. | | Key Market Dynamics | Intensifying competition and evolving regulatory frameworks shape the Keytruda market dynamics in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the overall market valuation of the South Korea keytruda market in 2024?** A: The overall market valuation was $677.17 Million in 2024. **Q: What is the projected market valuation for the South Korea keytruda market by 2035?** A: The projected market valuation for 2035 is $1783.33 Million. **Q: What is the expected CAGR for the South Korea keytruda market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 9.2%. **Q: Which cancer type had the highest market valuation in 2024 within the South Korea keytruda market?** A: Lung cancer had the highest market valuation, ranging from $250.0 Million to $600.0 Million in 2024. **Q: What are the market valuations for stomach cancer in the South Korea keytruda market?** A: The market valuations for stomach cancer ranged from $150.0 Million to $350.0 Million in 2024. **Q: Which distribution channel is projected to have the highest market valuation in the South Korea keytruda market?** A: Specialty pharmacies are projected to have the highest market valuation, ranging from $377.17 Million to $983.33 Million. **Q: Who are the key players in the South Korea keytruda market?** A: Key players in the market include Merck & Co, Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Novartis AG, Pfizer Inc, Eli Lilly and Company, and Amgen Inc. **Q: What was the market valuation for urothelial carcinoma in 2024?** A: The market valuation for urothelial carcinoma ranged from $127.17 Million to $433.33 Million in 2024. **Q: How did the market for Hodgkin lymphoma perform in 2024?** A: The market for Hodgkin lymphoma had a valuation ranging from $50.0 Million to $150.0 Million in 2024. **Q: What is the market valuation range for hospital pharmacies in the South Korea keytruda market?** A: The market valuation range for hospital pharmacies was from $300.0 Million to $800.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-keytruda-market-45320*